Anti-Mouse RANKL (CD254) - PE
Code | Size | Price |
---|
LEI-R1356-50ug | 50 ug | £223.00 |
Quantity:
LEI-R1356-200ug | 200 ug | £364.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG2a κ
Antibody Clonality: Monoclonal
Antibody Clone: IK22/5
Regulatory Status: RUO
Target Species: Mouse
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
RANKL is expressed on activated T cells and osteoclasts.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Mouse RANKL (NSO-derived)
Long Description:
RANKL antibody, clone IK22/5, recognizes receptor activator of NF-κB ligand (RANKL), also known as CD254, TNF-related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF). RANKL is a type II transmembrane protein belonging to the TNF cytokine superfamily and binds to the signaling receptor, RANK, or decoy receptor, osteoprotegerin (OPG). RANKL is expressed on osteoclasts and is essential for osteoclast differentiation, activation, and survival1. RANKL is also expressed on activated T cells and regulates T cell-dendritic cell (DC) interactions, enhancing DC activation and survival2-3. In addition, RANKL is crucial for lymph node, bone marrow, and thymus development4. Treatment with denosumab, an antibody directed against RANKL, is approved for the treatment of patients at high risk for bone fractures, including osteoporosis, and has shown anti-tumor effects5.
NCBI Gene:
21943
Target:
RANKL
References
1. Park JH, et al. (2017) Mol Cells. 40(10):706-713
2. Wong BR, et al. (1997) J Biol Chem. 272(40):25190-4
3. Anderson, D. M., et al. (1997) Nature 390:175.
4. Ono T, et al. (2020) Inflamm Regen. 2020;40:2.
5. de Groot AF, at al. (2018) Cancer Treat Rev. 62:18-28
Related Products
Product Name | Product Code | Supplier |
---|